ERYtech Pharma Announces Fast Take-off of Its Phase IIb Study in Acute Myeloid Leukemia
7/8/2013 10:47:10 AM
Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!
LYON, France--(BUSINESS WIRE)--Regulatory News: ERYTECH (NYSE Euronext Paris : FR0011471135 - ERYP) (Paris:ERYP), a French biopharmaceutical company that develops innovative treatments for acute leukemia and other oncology indications with unmet medical needs, announces a fast take-off of its Phase IIb study in Acute Myeloid Leukemia (AML). The study, a multicentre, open, randomized, controlled Phase IIb trial evaluating efficacy and tolerability of GRASPA® in the treatment of newly diagnosed acute myeloid leukemia (AML) patients, over 65 years, unfit for intensive chemotherapy, was initiated in March 2013.
Help employers find you! Check out all the jobs and post your resume.
comments powered by